- Entry
- $1.42
- Now
- $1.40 -1.1%
- Target
- —
- Score
- —
Five weeks back, I posted a basket of small/mid-cap biotech catalyst setups. Enough has happened that I owe a scorecard, and I'm including the one that hasn't worked so this isn't just a highlight reel. Disclosure up front, I'm long several of these, and none of this is advice, do your own work. VRDN (Viridian), the highest-conviction name. FDA approved veligrotug on June 26, launched as Lumvoa, the first drug cleared for both active and chronic thyroid eye disease. The …
— ORIGINAL POST ·
5 of the 6 biotech names I posted 5 weeks ago hit their catalyst (and the 1 that hasn't)
· r/pennystocks
· Jul 2, 2026